NCT02621905View on ClinicalTrials.gov

Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Neutropenia
Interventions
DRUG

Sporanox

At least 2 capsules twice a day for 3 weeks

DRUG

Lozanoc

At least 2 capsules twice a day for 3 weeks

Trial Locations (1)

2010

St Vincent's Hospital, Darlinghurst

All Listed Sponsors
lead

Mayne Pharma International Pty Ltd

INDUSTRY

NCT02621905 - Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg | Biotech Hunter | Biotech Hunter